Brind.

Leerink partners reiterated a Buy rating on Novocure Limited, citing solid results regarding its Optune/TTFields therapy.

2 reports, 2 independent Updated Aug 14
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Leerink partners reiterated a Buy rating on Novocure Limited, citing solid results regarding its Optune/TTFields therapy.

Who's involved

What this event is mainly about
Novocure (Jersey)Leerink partners

How it developed

Newest first. Tap a step to see who reported it.
  1. Analyst reiterated Buy rating on Novocure based on solid results for Optune.1 source
  2. Novocure reported revenue of $19.1M (Germany), $9.5M (Japan), and $18.4M (France) from sales of its therapy.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyLeerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jona
  • Business WireNovocure Reports Second Quarter 2025 Financial Results Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PAN